SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+32.69%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$324M
AUM Growth
+$324M
(+21%)
Cap. Flow
-$75.2M
Cap. Flow
% of AUM
-23.19%
Top 10 Holdings %
Top 10 Hldgs %
40.14%
Holding
88
New
16
Increased
27
Reduced
15
Closed
20
Top Buys
| 1 |
Nuvalent
NUVL
|
$14.2M |
| 2 |
Rocket Pharmaceuticals
RCKT
|
$11.5M |
| 3 |
Medtronic
MDT
|
$11.1M |
| 4 |
Sanofi
SNY
|
$10.9M |
| 5 |
Celldex Therapeutics
CLDX
|
$9.8M |
Top Sells
| 1 |
Praxis Precision Medicines
PRAX
|
$85.4M |
| 2 |
IMGN
Immunogen Inc
IMGN
|
$20.7M |
| 3 |
Soleno Therapeutics
SLNO
|
$11.9M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$9.22M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
$8.76M |
Sector Composition
| 1 | Healthcare | 99.98% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Roivant Sciences
ROIV
$8.15B
| – | – | -100,000 | Closed | -$1.17M |
|
77
Reviva Pharmaceuticals
RVPH
$30.6M
| – | – | 0 | – | – |
|
78
Sagimet Biosciences
SGMT
$244M
| – | – | -100,000 | Closed | -$880K |
|
|
SLRN
79
DELISTED
ACELYRIN
SLRN
| – | – | 0 | – | – |
|
80
Syndax Pharmaceuticals
SNDX
$1.41B
| – | – | -20,000 | Closed | -$290K |
|
81
Vertex Pharmaceuticals
VRTX
$100B
| – | – | -13,765 | Closed | -$4.79M |
|
82
Voyager Therapeutics
VYGR
$186M
| – | – | -103,966 | Closed | -$806K |
|
83
SPDR S&P Biotech ETF
XBI
$5.07B
| – | – | 0 | – | – |
|
|
CLYM
84
Climb Bio, Inc. Common Stock
CLYM
$151M
| – | – | -121,110 | Closed | -$319K |
|
|
IMGN
85
DELISTED
Immunogen Inc
IMGN
| – | – | -1,307,435 | Closed | -$20.7M |
|
|
MRTX
86
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – | -200,000 | Closed | -$8.71M |
|
|
PNT
87
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| – | – | -93,700 | Closed | -$625K |
|
|
ELOX
88
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
| – | – | -54,075 | Closed | -$260K |
|